ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 605

Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany

Klaus Krüger1, Gerd R. Burmester2, Siegfried Wassenberg3, Astrid Thiele4 and Matthias H. Thomas5, 1Medical Centre of Rheumatology, Munich, Germany, 2Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 3Rheumazentrum Ratingen, Ratingen, Germany, 4Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, 5Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Biologics, observation, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in patients (pts.) with active RA after treatment with at least one TNFi in a RCT. However, data on effectiveness and patient-reported outcomes (PROs) under daily clinical practice conditions are required.
The aim is to assess the effectiveness of GLM as second line bDMARD therapy in patients with established RA, PsA or AS who had received TNFi pretreatment.

Methods: Subanalysis of the non-interv., prospective, 24-month (24 mo) study GO-NICE in pts. with established RA, PsA or AS starting with GLM 50mg SC once monthly as second line TNFi after one previous TNFi in a real life setting in Germany (158 sites). Disease activity was assessed with DAS28, PsARC and BASDAI. PROs included QoL (EQ-5D-3L), functionality (FFbH), and fatigue (FACIT-F).

Results: 358 pts. were eligible. They had previously received ADA (177), CZP (3), ETA (119), or IFX (59). 147 pts. (41.1%) completed the study until month 24.

RA pts. (n=98): Mean age 55.6 yrs., 73 (74.5%) patients were female, 67 (68.4%) were rheumatoid factor (RF) positive, and 71 (74.0%) had anti ccp-antibodies at BL. DAS28 score at BL dropped significantly from 5.0 to 4.2 after 3 months (m3) to 2.8 points (m24) (p<0.0001 vs. BL), (in bDMARD-naïve patients: 5.0, 3.6 to 2.9). After 3m of treatment, 47.4% of pts. had LDA or were in remission (DAS28 ≤3.2), after 24 mo 62.5%.

PsA pts. (n=134): Mean age 50.8 yrs., 68 (50.7%) were males, 120 pts. (89.6%) had extra-articular manifestations at BL. The proportion of pts. achieving a response (PsARC) was 51.3% at m3, and 52.1% at m24, respectively, (bDMARD-naïve: 64,0%, and 77,7%).

AS-pts. (n=126): Mean age 45.2 yrs., 79 (62.7%) were males, 101 (80.2%) were HLAB27+, 44 pts. (35.5%) had extra articular manifestations at BL. The BASDAI dropped significantly from 4.9 at BL to 3.1 (m3) to 2.9 within 24 months (p<0.0001 vs. BL), (bDMARD-naïve: 5.0, 2.5 to 2.0).

An improvement of quality of life (QoL) was seen after 6 months and was maintained over 24 months: The pts.’ health status (EQ VAS) improved significantly (p<0.001 vs. BL) from 48.4 to 64.4 (RA), from 47.8 to 62.9 (PsA) and from 45.5 to 60.8 (AS). The functional ability (FFbH) improved significantly (p<0.05 vs. BL) from 63.4 to 73.5 points (RA), and from 67.4 to 76.2 (AS), changes at m24 vs. BL in pts. with PsA were n.s. The mean fatigue score (FACIT–F) increased significantly (p<0.003 vs. BL) from 30.8 to 38.2 points (RA), and from 28.8 to 34.4 points (AS), changes at m24 vs. BL in pts. with PsA were n.s. No new safety signals were detected.

Difference BL to m24

[STD] p

RA: DAS28

AS: BASDAI

(2nd line, after one TNFi)

-2.23 ±0.30
[-2.82,-1.64] <.0001

-2.02 ±0.32
[-2.65,-1.39] <.0001

(bDMARD-naïve)

-2.10 ±0.15
[-2.39,-1.81] <.0001

-2.89 ±0.20
[-3.29,-2.49] <.0001

Conclusion: GLM 50 mg SC once monthly as second-line TNFi in pts. with RA, PsA or AS who had previously received pretreatment with another TNFi was also effective and showed remarkable improvements in clinical parameters, patient-reported quality of life, functionality, and fatigue parameters within 3 (and 6) months. These effects were maintained over 24 mo. Overall results were consistent with those in patient who received GLM as first TNFi.


Disclosure: K. Krüger, MSD Sharp Dohme GmbH, 9,AbbVie Inc., 9,BMS, 9,Celgene Corporation, 9,Janssen, 9,Lilly, 9,Pfizer, Inc., 9,Sanofi-Aventis, 9,UCB, Inc., 9; G. R. Burmester, AbbVie, BMS, Lilly, MSD, Pfizer, Roche, 5; S. Wassenberg, AbbVie, Chugai, Janssen Biologics, MSD, Novartis, Pfizer, Roche, and UCB, 5; A. Thiele, MSD Sharp Dohme GmbH, 9,Biogen, 9,Celgene Corporation, 9,Chugai, 9,Hexal, 9,Janssen, 9,Lilly, 9,Novartis, 9,Pfizer, Inc., 9,UCB, Inc., 9; M. H. Thomas, MSD Sharp & Dohme GmbH Germany, 3.

To cite this abstract in AMA style:

Krüger K, Burmester GR, Wassenberg S, Thiele A, Thomas MH. Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinical-outcomes-of-golimumab-as-second-line-tnf-inhibitor-treatment-in-patients-with-rheumatoid-arthritis-ra-psoriatic-arthritis-psa-or-ankylosing-spondylitis-as-subanalysis-of-a-no/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-outcomes-of-golimumab-as-second-line-tnf-inhibitor-treatment-in-patients-with-rheumatoid-arthritis-ra-psoriatic-arthritis-psa-or-ankylosing-spondylitis-as-subanalysis-of-a-no/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology